Axon Therapies Inc.

Attending #THT2024 this week in Boston? Don't miss the Tues., Mar. 5 session at 2pm ET -- "Featured Late-Breaking Clinical Science Abstracts I" -- where you can hear from Sanjiv Shah, MD about the 12-month results of our REBALANCE-HF trial, the largest randomized device feasibility study in #HFpEF. https://lnkd.in/eU3ZwnWC #SAVM #HeartFailure #Cardiology

#OurHearts beat for yours! Happy Valentine’s Day❤️

It’s National #WearRedDay, a day to raise awareness for a cause that’s central to our work and to our hearts. During #AmericanHeartMonth, it’s especially important to remember that heart disease is the leading cause of death among women. Get more information, tools, and resources at https://lnkd.in/dkxtiYsm. #HeartMonth #OurHearts #HeartDisease #HeartDiseaseAwareness

This recently published paper in the Journal of Cardiac Failure provides an excellent overview of our REBALANCE-HF study, the largest randomized device feasibility study in #HFpEF. The paper discusses the methods and results of the study, including detail on the #SAVM procedure and mechanism of action, as well as positive clinical outcomes in the initial roll-in cohort. Take a look!   Thank you to the authors and study investigators Marat Fudim, Sheldon Litwin, Barry Borlaug, Rajeev Mohan, Matthew Price, Peter Fail, Teona Zirakashvili, Tamaz Shaburishvili, Parag Goyal, Scott Hummel, Ravi Patel, Vivek Reddy, Daniel Burkhoff, Manesh Patel, MD, Sami Somo, Ph.D., and Sanjiv Shah for all your work that makes this groundbreaking cardiac research possible.

We thoroughly enjoyed attending and presenting at CSI congress' Device Heart Failure Conference in Frankfurt this past weekend. The presentation by Axon Founder & Senior Clinical Advisor Howard Levin, MD about our #SAVM procedure and the REBALANCE-HF study was well-received by an engaged, attentive audience, and good conversations were had between sessions. Learn more about the therapeutic approach we're pioneering at axontherapies.com.

Attending CSI congress' Focus D-HF 2023 this weekend in Germany? Hear from Axon Senior Clinical Advisor & Board Member Howard Levin, MD about splanchnic nerve modulation in #HFpEF in the Friday 9:20 – 10:40 CET session "Neuromodulation in the Management of Heart Failure and its Comorbidities: Diabetes, Sleep Apnea, Hypertension and Arrhythmias." #SAVM #HeartFailure https://lnkd.in/dmr9jYg4

This year has seen a lot of growth in Axon's clinical team. We want to take a moment to recognize one of our newest leaders, Holly Keller BSN RN CCRA, who's brought her extensive experience in medical device and biopharma clinical trial monitoring to Axon to lead our clinical operations. Holly's already made an impact aligning the vision of cross-functional teams to drive compliance and support data integrity. We're thrilled to have her on our team! Learn about what it's like to work at Axon at axontherapies.com/careers.